García-Ortiz R

Language: Spanish
References: 19
Page: 4-6
PDF size: 59.35 Kb.

Text Extraction

No abstract

REFERENCES

1. Gómez-Cruz JR. Comparación de dos dosis de I131 (20 vs 29 mCi) en el tratamiento del hipertiroidismo autoinmune. Rev Endocr Nutr 2011; 19: 17-20.

2. Bahan RS, Burch HB, Cooper DS. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011; 17(3): 456-520.

3. Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Cosgrove DO, Harmer CL. Low-dose 131I in treatment of Graves’ disease. J R Soc Med 1985; 78: 197-202.

4. Wartofsky L, Glinoer D, Solomon B et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-135.

5. Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves’ disease [abstract]. J Clin Invest 1942; 21: 624-630.

6. Hamilton J, Lawrence JH. Recent clinical developments in the therapeutic application of radio-phosphorus and radioiodine. J Clin Invest 1942; 624: 1942.

7. Chapman EM, Evans RD. The treatment of hyperthyroidism with radioactive iodine. JAMA 1946; 131: 86-90.

8. Pollard WG. Availability of radioactive isotopes. Science 1946; 103: 697-705.

9. Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 131I therapy for Graves’ disease. Clin Endocrinol 1988; 28: 487-496.

10. Von Hofe SE, Dorfman SG, Carretta RF, Young RL. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med 1978; 19: 180-184.

11. Ratcliffe GE, Fogelman I, Maisey MN. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime. Br J Radiol 1986; 59: 1105-1107.

12. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long-term follow up study. Br Med J 1984; 289: 361-363.

13. Rapoport B, Caplan R, DeGroot LJ. Low-dose sodium iodide 131I therapy in Graves disease. JAMA 1973; 224: 1610-1613.

14. McDougall IR, Greg WR. Combined carbimazole-131-I treatment for thyro-toxicosis. Scott Med J 1972; 17: 57-61.

15. Grosso M, Traino A, Boni G et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm 2005; 20: 218-223.

16. Leslie W, Ward L, Salamon E et al. A Randomized comparison od radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 2003; 88: 978-983.

17. Rooij A, Vandenbroucke J, Smit JW et al. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 2009; 161: 771-777.

18. Nygaard B, Hegedüs L, Gervil M et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves’ disease. J Intern Med 1995; 238: 491-497.

19. Sridama V, McCormick M, Kaplan EL et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N Engl J Med 1984; 311: 426-432.